|
Patent landscape, scope, and claims: |
United States Drug Patent 5,698,558: Scope, Claims, and Landscape Analysis
United States Patent 5,698,558, titled "Method of Treating Inflammatory Conditions with Substituted Benzoyl Phenyl Ureas," was granted on December 16, 1997, to Wyeth. The patent describes a method for treating inflammatory conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease, by administering a specific class of substituted benzoyl phenyl urea compounds. These compounds function as inhibitors of tumor necrosis factor-alpha (TNF-alpha), a key cytokine implicated in various inflammatory processes. The patent's claims define the therapeutic use of these chemical entities, laying the groundwork for their potential application in a significant therapeutic area.
What are the core therapeutic indications claimed in Patent 5,698,558?
The primary therapeutic indications claimed in United States Patent 5,698,558 are inflammatory conditions. Specifically, the patent details methods of treating:
- Rheumatoid Arthritis: A chronic autoimmune disease characterized by inflammation of the joints.
- Psoriasis: A chronic autoimmune skin disease that causes red, itchy, scaly patches.
- Crohn's Disease: A chronic inflammatory bowel disease that affects the digestive tract.
- Other Inflammatory Conditions: The patent broadly covers other conditions where TNF-alpha plays a pathogenic role.
The mechanism of action described is the inhibition of tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a pro-inflammatory cytokine that contributes to the pathogenesis of these diseases. By reducing TNF-alpha levels or activity, the claimed compounds aim to alleviate the inflammatory symptoms associated with these conditions.
What specific chemical compounds are protected by the patent's claims?
Patent 5,698,558 protects a genus of substituted benzoyl phenyl urea compounds. The claims define these compounds by their chemical structure and specific substituents. The core structure involves a benzoyl group and a phenyl urea moiety.
The key defining features of the compounds are:
- General Formula: The patent outlines a general formula (Formula I) encompassing a range of structural variations.
- Substituents: The specific activity and therapeutic utility are linked to the presence and position of various substituents on the aromatic rings of the benzoyl and phenyl urea portions. These substituents can include halogens, alkyl groups, alkoxy groups, and other functional groups.
- Specific Examples: The patent provides a detailed list of specific, exemplified compounds within this genus that were synthesized and tested. These examples are crucial for understanding the practical scope of the patent. For instance, Example 1 describes the synthesis of 4-amino-N-[4-(2-chloro-4-fluorophenyl)carbamoyl]benzamide, a representative compound within the claimed class.
The patent's claims are structured to cover a broad range of related chemical entities that share the core substituted benzoyl phenyl urea scaffold and exhibit the desired TNF-alpha inhibitory activity.
What is the claimed method of treatment?
The claimed method of treatment in Patent 5,698,558 involves the administration of a therapeutically effective amount of a compound belonging to the protected genus to a subject in need of such treatment.
Key aspects of the claimed method include:
- Dosage and Administration: The patent specifies that the compound is administered in a therapeutically effective amount. While specific dosage ranges are not universally defined for all embodiments, the examples and general description suggest dosages intended to achieve the desired therapeutic outcome. Routes of administration are not strictly limited but would typically be oral or parenteral for systemic inflammatory conditions.
- Therapeutic Goal: The objective of the administration is to treat or ameliorate inflammatory conditions by inhibiting TNF-alpha.
- Formulations: The patent implies that the active compounds can be formulated into various pharmaceutical compositions suitable for administration. These compositions would include the active ingredient along with pharmaceutically acceptable carriers, diluents, or excipients.
The method of treatment claims are directed towards the practical application of the disclosed chemical compounds for therapeutic benefit, focusing on the act of administering the drug and its intended effect.
What is the commercial significance and patent landscape surrounding TNF-alpha inhibitors?
The patent landscape for TNF-alpha inhibitors is extensive and highly competitive, reflecting the significant commercial success of this class of drugs. Many blockbuster therapies have been developed targeting TNF-alpha for inflammatory diseases.
Key aspects of the commercial significance and landscape include:
- Blockbuster Drugs: TNF-alpha inhibitors like infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), and golimumab (Simponi) have generated billions of dollars in revenue annually. These drugs have revolutionized the treatment of chronic inflammatory diseases.
- Patent Expirations and Generics: Many of the foundational patents for these early TNF-alpha inhibitors have expired or are nearing expiration, opening the door for generic and biosimilar competition. This has led to significant price erosion in the market for some of these therapies.
- Newer Generations and Mechanisms: Pharmaceutical companies continue to innovate in the TNF-alpha space and related inflammatory pathways. This includes developing next-generation inhibitors with improved efficacy, safety profiles, or different routes of administration. Research also extends to targeting other cytokines or intracellular signaling pathways involved in inflammation.
- Patent 5,698,558's Position: United States Patent 5,698,558, granted in 1997, covers a specific chemical class of substituted benzoyl phenyl ureas. Its commercial impact is directly tied to whether compounds falling under its claims were successfully developed and commercialized by Wyeth or its successors. The breadth of its claims and the specific nature of the exemplified compounds determine its potential overlap and interference with other patents in the TNF-alpha inhibitor field.
- Intellectual Property Strategy: Companies in this space employ robust intellectual property strategies, including filing patents on new chemical entities, novel formulations, specific medical uses, and manufacturing processes. This creates a complex web of patent rights that can influence market entry and competition.
Understanding the patent landscape is critical for assessing the freedom to operate for new drug candidates and for identifying potential licensing or litigation risks.
What are the key claims and their scope in Patent 5,698,558?
United States Patent 5,698,558 contains multiple claims that define the protected intellectual property. The claims are meticulously drafted to cover the disclosed invention.
Key claims and their scope:
- Claim 1 (Method of Treatment): This independent claim broadly defines a method of treating an inflammatory condition by administering a compound of Formula I. The scope is defined by Formula I and the specified inflammatory conditions.
- Dependent Claims: Numerous dependent claims refine and narrow the scope of Claim 1 by specifying particular substituents, preferred embodiments, or particular inflammatory conditions. For example, dependent claims might specify particular halogen substitutions, alkyl chain lengths, or define the compound as being of a specific subclass within Formula I.
- Definition of Formula I: The scope of all claims referencing Formula I is determined by the detailed structural definition and the permissible range of substituents outlined in the patent specification. This includes specific groups that can be attached at various positions on the aromatic rings.
- Therapeutically Effective Amount: The claims define the amount of compound to be administered as "therapeutically effective," which is a functional limitation requiring demonstration of efficacy in treating the specified conditions.
- Exemplified Compounds: While the claims define a genus, the exemplified compounds provide concrete embodiments and are often used to interpret the breadth and intent of the claims.
The scope of the patent is therefore defined by the combination of its structural definitions, the specified therapeutic uses, and the overarching methodology of administration. It is designed to protect a specific chemical class and its application in treating inflammatory diseases through TNF-alpha inhibition.
What are the expiration dates and remaining term of Patent 5,698,558?
United States Patent 5,698,558 was granted on December 16, 1997.
- Original Term: Under the patent laws in effect at the time of its grant, the patent term was generally 17 years from the date of grant or 20 years from the date of application, whichever was longer. For a patent granted in 1997, the term calculation would typically default to 20 years from the application filing date.
- Application Filing Date: To determine the exact expiration, the application filing date is required. Assuming a typical filing date in the mid-1990s for a patent granted in 1997, the patent would likely have expired around the mid-2010s.
- Patent Term Adjustment (PTA) and Extensions: It is possible that the patent term was extended due to Patent Term Adjustment (PTA) for USPTO delays or through a patent term extension (PTE) for regulatory delays, particularly if a drug based on this patent underwent FDA review. However, without specific information on these adjustments, the default expiration would be based on the application filing date.
As of 2023, it is highly probable that United States Patent 5,698,558 has expired. Pharmaceutical patents filed in the mid-1990s would have reached their statutory expiration date by this point, even with potential adjustments.
To confirm the precise expiration date, one would need to consult the official United States Patent and Trademark Office (USPTO) database, which provides the definitive patent term information, including any granted extensions.
What is the competitive patent landscape for TNF-alpha inhibitors?
The competitive patent landscape for TNF-alpha inhibitors is characterized by numerous patents covering various aspects of these therapies, including chemical structures, therapeutic uses, formulations, and manufacturing processes.
Key elements of the competitive landscape include:
- Pioneering Patents: Early patents, such as those for etanercept, infliximab, and adalimumab, established the foundational intellectual property for the first generation of TNF-alpha inhibitors. These patents are largely expired or nearing expiration.
- Composition of Matter Patents: These are the strongest patents, protecting the unique chemical structures of the drug molecules themselves. Patents like 5,698,558 fall into this category if they claim specific novel compounds.
- Method of Use Patents: These patents claim specific therapeutic applications for known compounds, such as using a particular drug to treat a specific inflammatory disease. Patent 5,698,558 is primarily a method of use patent.
- Formulation and Delivery Patents: Patents covering specific ways to formulate a drug (e.g., extended-release formulations, specific excipients) or deliver it (e.g., autoinjectors) can extend market exclusivity.
- Process Patents: These protect the methods used to manufacture the active pharmaceutical ingredient.
- Biosimil and Generic Competition: With the expiry of key patents, the market has seen the rise of biosimil versions of biologics like infliximab and adalimumab, and generic versions of small molecule inhibitors. This intense competition lowers prices and increases market access.
- Evergreening Strategies: Pharmaceutical companies often employ strategies to extend patent protection, such as filing new patents on incremental improvements or new indications for existing drugs.
- Interference Proceedings and Litigation: The dense patent landscape frequently leads to patent interference proceedings (challenging priority of invention) and patent litigation (alleging infringement).
The patent landscape for TNF-alpha inhibitors is a dynamic environment where innovation continues, but the impact of early patents is diminishing due to expiration, paving the way for broader market access by biosimil and generic competitors.
What are the potential implications of Patent 5,698,558 for current or future drug development?
The implications of United States Patent 5,698,558 for current or future drug development depend on several factors, primarily whether any compounds covered by its claims were successfully developed and commercialized, and the status of its expiration.
Potential implications:
- Historical Context: The patent provides historical context for the development of TNF-alpha inhibitors, demonstrating early efforts to identify and patent chemical classes targeting this pathway.
- Freedom to Operate: Given its 1997 grant date, the patent has likely expired. This means that compounds falling under its scope are now in the public domain, free for others to develop and commercialize, provided they do not infringe on other, later-expiring patents (e.g., patents on specific formulations, manufacturing processes, or newer indications for these compounds).
- Platform for Further Research: The chemical scaffolds and structure-activity relationships disclosed in the patent may still serve as a starting point for further research and development. Scientists could use this as a basis for designing novel analogs with potentially improved properties, while ensuring their new inventions are not covered by existing, still-active patents.
- Licensing and Acquisition Opportunities (Historical): In its active life, this patent would have represented a significant asset for Wyeth, potentially forming the basis for licensing agreements or acquisitions by companies seeking to enter the TNF-alpha inhibitor market.
- Litigation Risk (Historical): For companies developing TNF-alpha inhibitors, understanding the claims and expiration dates of patents like 5,698,558 was crucial for assessing infringement risk and planning litigation strategies.
- Guidance for New Chemical Entities: While the patent itself is likely expired, the claims and disclosure can offer insights into patenting strategies for new chemical entities targeting similar biological pathways. It informs what was considered novel and inventive at the time, guiding current patent prosecution efforts.
In summary, as an expired patent, 5,698,558's primary implication now is its contribution to the historical body of knowledge in TNF-alpha inhibition and the removal of its specific claims from the active patent landscape, enabling broader freedom to operate within its scope.
Key Takeaways
- United States Patent 5,698,558, granted in 1997 to Wyeth, protects a method of treating inflammatory conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease, through the administration of substituted benzoyl phenyl urea compounds that inhibit tumor necrosis factor-alpha (TNF-alpha).
- The patent's claims define a genus of chemical compounds based on a specific structural scaffold and specify their therapeutic application and mechanism of action.
- The TNF-alpha inhibitor market is substantial, with numerous blockbuster drugs and significant ongoing competition, including biosimil and generic entrants.
- Given its 1997 grant date, United States Patent 5,698,558 has likely expired, removing its claims from active patent protection and increasing freedom to operate within its disclosed scope.
- The patent contributes to the historical understanding of TNF-alpha inhibitor development and may serve as a basis for future research into related chemical structures, provided new inventions are differentiated and do not infringe on other active patents.
Frequently Asked Questions
-
Did compounds claimed in Patent 5,698,558 reach the market?
Confirmation requires tracing Wyeth's product pipeline and specific drug approvals related to substituted benzoyl phenyl ureas. Patent filings do not always directly translate to commercialized products.
-
Are there any active patents that claim compounds structurally similar to those in Patent 5,698,558?
A comprehensive patentability search and freedom-to-operate analysis would be necessary to identify any overlapping or similar active patent claims.
-
What were the primary challenges in developing TNF-alpha inhibitors based on this patent?
Challenges could include achieving sufficient efficacy, managing side effects, drug formulation, and navigating the complex regulatory approval process, in addition to overcoming prior art and existing patent landscapes.
-
Can a generic version of a drug developed under this patent be marketed now?
If a specific drug was developed and approved based on this patent, its generic market entry would depend on the expiration of the specific drug patent (which may have its own term extension) and any associated exclusivities.
-
How does Patent 5,698,558 relate to biologic TNF-alpha inhibitors like Humira or Enbrel?
Patent 5,698,558 covers small molecule chemical entities, whereas Humira and Enbrel are biologic drugs (monoclonal antibodies or fusion proteins). They target the same pathway but represent distinct classes of therapeutics with different patent protection strategies.
Citations
[1] United States Patent 5,698,558. (1997). Method of treating inflammatory conditions with substituted benzoyl phenyl ureas. Wyeth. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
